Navigation Links
Onyx Pharmaceuticals Provides Status Update on Carfilzomib
Date:10/7/2010

EMERYVILLE, Calif., Oct. 7 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will delay its New Drug Application (NDA) filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls (CMC) review division of the U.S. Food and Drug Administration (FDA).  The FDA has requested additional CMC information related to commercial-scale manufacturing of carfilzomib.  Onyx had previously anticipated filing an NDA by the end of 2010 for accelerated approval of carfilzomib and now expects that its NDA filing for accelerated approval could occur as early as mid-year 2011.

The clinical profile of carfilzomib has not changed, and no new safety signals have been observed. The Phase 3 trials are on schedule and actively enrolling patients, and this change is not expected to impact any of the carfilzomib trials or other development plans.

In preparation for commercial-scale production, the company made manufacturing process enhancements in the production of carfilzomib, which are customary when migrating from clinical to commercial-scale manufacturing.  In a recently completed manufacturing-scale run, the company observed minor variations that are believed to be primarily related to equipment temperature variances.  In response to FDA's request, Onyx is providing the agency with additional CMC information.  Onyx has additional data and is generating more information to share as part of the ongoing dialogue with the CMC review division in preparation for an NDA filing.

"We are confident in the clinical and preclinical data package supporting the carfilzomib NDA and in our manufacturing strategy," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "We believe that by providing this supportive data, we will strengthen our NDA package, thus enabling us to bring carfilzom
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that James ... has been elected to the Company,s Board of Directors, ... Anderson , Executive Chairman of CryoLife, stated, "Since joining the ... excellent leader who is well positioned to maximize CryoLife,s ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms ... subtle or unnoticed, but new technology, coupled with ... and leading to earlier detection of eye diseases, ... 29 million Americans. If left untreated, these diseases ... blindness. Recently, optometric researchers have ...
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics ... MA is revolutionizing spinal cord injury (SCI) ... been shown to outperform in tissue regrowth in the ... scaffold.  Made from an FDA approved polymer, the scaffold ... it harmless to the human body. NVIV has recently ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... , , , , PORTSMOUTH, Va., Dec. ... away over $6,000,000 worth of its new LifeGuard30(TM) medical ... afford to buy them as well as to charitable and non-profit ... stores and displays vital patient information at the scene of a ...
... , , , , , , SEATTLE, Dec. ... today that on December 24, 2009, CTI,s Board of Directors (the ... "Rights Plan") in which one preferred stock purchase right will be ... business on January 7, 2010. Initially, the rights are not exercisable, ...
Cached Medicine Technology:ViVre Medical Announces $6,000,000 Gift 2ViVre Medical Announces $6,000,000 Gift 3Cell Therapeutics, Inc. Adopts Shareholder Rights Plan 2Cell Therapeutics, Inc. Adopts Shareholder Rights Plan 3Cell Therapeutics, Inc. Adopts Shareholder Rights Plan 4
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... who quickly add weight and length may be showing a ... In adults, certain genes have been linked to increased ... gains in fat and lean muscle, the researchers said. ... and taller. By ages 2 and 3, however, these genes ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/20/2014)... 2014 The newly updated Worldwide Medical ... thousands of facts, figures and forecasts on the global ... sector forecast categories the Worldwide Medical Market Forecasts ... national views on the worldwide medical market to reveal ... gives you data for 2010-2019, covering each country market ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... City based non-profit organization that helps New Yorkers ... lasting, positive changes toward health, housing, recovery and ... who have transformed the local community through their ... Managing Director, Marc Shapses , has been ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... Disparities in Diabetes Prevention and Management Among Most ... Foundation (Foundation), the philanthropic arm of Merck & ... Alliance to Reduce Disparities in Diabetes (Alliance), a ... those populations most at risk for diabetes -- ...
... Diamonds and Jewels ... Jet Set Getaways ... Exclusive ... to Cure Paralysis BAL HARBOUR, Fla., Feb. 25 ... designers and the highest concentration of world-class jewelers and ... dazzling treasures for Destination Fashion 2009,s silent ...
... Discovery of brain area responsible for link could lead to ... -- The memories and emotions that people associate with ... a part of the brain where the wiring for memories ... study says. , The finding, published Feb. 24 in ...
... Medicine Featured March 7-12 in San Diego ... Interventional Radiology (SIR) will present the latest research ... bone cancer; herniated disks; peripheral arterial disease (PAD) ... its 34th Annual Scientific Meeting, March 7-12 at ...
... 24 states now reporting widespread activity, the nation,s infectious ... to educate their customers on when antibiotics are the ... good. , Several grocery store chains nationwide began offering ... to cold and flu season, despite the fact that ...
... itself Kurt Salmon Associates saysNEW YORK, Feb. 25 ... less on prescription drugs this year versus last ... to Kurt Salmon Associates, recent evaluation of more than ... a continued shift towards lower-cost generic drugs and an ...
Cached Medicine News:Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 2Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 3Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 4Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 5Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 6Health News:Spectacular Ultra-Luxe Auction for Destination Fashion 2009, Presented by Stewart Rahr, Best of Bal Harbour's Brands Contribute More Than $250,000 Worth of Exclusive Items 2Health News:Spectacular Ultra-Luxe Auction for Destination Fashion 2009, Presented by Stewart Rahr, Best of Bal Harbour's Brands Contribute More Than $250,000 Worth of Exclusive Items 3Health News:Spectacular Ultra-Luxe Auction for Destination Fashion 2009, Presented by Stewart Rahr, Best of Bal Harbour's Brands Contribute More Than $250,000 Worth of Exclusive Items 4Health News:Why Music Triggers a Walk Down Memory Lane 2Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 2Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 3Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 4Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 5Health News:Health experts urge supermarket pharmacies to 'get smart' about free antibiotics 2Health News:Consumers Spending Less on Prescription Drugs 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm round tip. Blade dimension: 16.5 mm x 5.2 mm x 3.8 mm x 2.4 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 11.1 mm x 1.5 mm x 5.7 mm....
Medicine Products: